A Phase 1 interventional study of FT1 and Placebo in Diarrhea Caused by Drug (Disorder), sponsored by Chongqing Peg-Bio Biopharm Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by Chongqing Peg-Bio Biopharm Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Diarrhea with a site in China — 19 open to participants now, 20 under way, 3 of them phase 3. Diarrhea · China.
Among the 50 studies in Diarrhea with a site in China, this one is the 33rd largest by enrollment of the 43 interventional ones that give a count, is one of 6 that started in 2024, is one of 5 in phase 1, and was the 34th registered.
880 studies on the registry are indexed under Diarrhea; 78 are open to participants now.
Browse Diarrhea studies →19 of the 50 studies in Diarrhea with a site in China are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in China, United States, Belgium and 7 more countries
Ages 18–75
Shenzhen Hospital of Southern Medical University · Sites in China
Ages 18+
Hubei Cancer Hospital · Sites in China
Ages 18–75
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18+ · Women only
Jinling Hospital, China · Sites in China
Ages 16–80 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 46 Diarrhea studies recruiting now, 21 (46%) set no upper age limit and 23 (50%) stop at 75 or younger; 19 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 17 · Phase 3 11 · Phase 4 3
First in 2005; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 137 across 740 interventional studies indexed under Diarrhea.
Median enrollment 180 across the 43 interventional studies, 80 across the 7 observational. Of the 17 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 50 have an industry lead sponsor. The 10 most frequent:
Chongqing Peg-Bio Biopharm Co., Ltd. is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
Chongqing Peg-Bio Biopharm Co., Ltd. has 1 study filed under Diarrhea — fewer than ten, so there is no comparison to draw.
6 of the studies in Diarrhea with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07309315Shenzhen Hospital of Southern Medical UniversityInactivated Bacteroides Fragilis for Prevention of Chemotherapy-Induced Diarrhea | 2026-12-30 |
| NCT07300462Shanghai United Cell Biotechnology Co., LtdA Post-marketing Observational Study of Oral Cholera Vaccine | 2027-01 |
| NCT07264985Hubei Cancer HospitalGut Microbiota and Diarrhea in Breast Cancer Patients Receiving Pyrotinib | 2027-06 |
| NCT06892093Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityProbiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients | 2027-06 |
| NCT07721012Lei Yunshang GroupHuanghou Zhixie Diwan in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D) | 2027-08-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 50 studies in Diarrhea with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main aim of this clinical trial is to assess the safety of FT1 in participants aged 18 to 45 years. The main questions it aims to answer are:
Participants will
This study is a first-in-human study, which is a single-center, randomized, placebo-controlled, double-blind, dose escalation clinical study, aiming to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of FT1 in healthy adult volunteers.
The trial is divided into 2 parts, single-dose part and multiple-dose part. In multiple-dose part, participants will receive once weekly subcutaneous injection of FT1 for 3 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single dose of FT1 will be administered, subcutaneous injection
Drug: FT1
A single dose of FT1 Placebo will be administered, subcutaneous injection
Drug: Placebo
FT1 will be administered once weekly for 3 weeks, subcutaneous injection
Drug: FT1
FT1 Placebo will be administered once weekly for 3 weeks, subcutaneous injection
Drug: Placebo
Six dose levels will be evaluated in single-dose part, and three dose levels in multiple-dose part.
Placebo will be administered.
Treatment-related Adverse Events
To evaluate the adverse events as characterized by type, frequency, severity as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, timing, seriousness, and relationship to study therapy after administration.
Time frame: up to 29 days in single-dose part, and up to 43 days in multiple-dose part
The Area Under the Curve from dosing to the time of the last measured concentration (AUC0-t)
Pharmacokinetic parameter
Time frame: up to 29 days in single-dose part, and up to 43 days in multiple-dose part
Maximum plasma concentration (Cmax)
Pharmacokinetic parameter
Time frame: up to 29 days in single-dose part, and up to 43 days in multiple-dose part
The half-life (t1/2)
Pharmacokinetic parameter
Time frame: up to 29 days in single-dose part, and up to 43 days in multiple-dose part
Anti-drug Antibody
Immunogenicity of FT1
Time frame: up to 29 days in single-dose part, and up to 43 days in multiple-dose part
Ran from Aug 2024 to primary completion in Aug 2025, 11 months.
Of 23 phase 1 interventional studies under Diarrhea, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 23. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chongqing Peg-Bio Biopharm Co., Ltd. →